Follow-up of phase I trial of adalimumab and rosiglitazone in FSGS: III. Report of the FONT study group

BACKGROUND: Patients with resistant primary focal segmental glomerulosclerosis (FSGS) are at high risk of progression to chronic kidney disease stage V. Antifibrotic agents may slow or halt this process. We present outcomes of follow-up after a Phase I trial of adalimumab and rosiglitazone, antifibr...

Descripción completa

Detalles Bibliográficos
Autores principales: Peyser, Alexandra, MacHardy, Nathaniel, Tarapore, Freya, MacHardy, Jacqueline, Powell, Leslie, Gipson, Debbie S, Savin, Virginia, Pan, Cynthia, Kump, Theresa, Vento, Suzanne, Trachtman, Howard
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Research article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2823728/
https://www.ncbi.nlm.nih.gov/pubmed/20113498
http://dx.doi.org/10.1186/1471-2369-11-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2823728/
https://www.ncbi.nlm.nih.gov/pubmed/20113498
http://dx.doi.org/10.1186/1471-2369-11-2

Ejemplares similares